An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01506167 |
Recruitment Status
:
Completed
First Posted
: January 9, 2012
Last Update Posted
: June 14, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Colorectal Cancer |
Study Type : | Observational |
Actual Enrollment : | 719 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma |
Actual Study Start Date : | July 6, 2012 |
Actual Primary Completion Date : | November 14, 2016 |
Actual Study Completion Date : | November 14, 2016 |

Group/Cohort |
---|
Cohort |
- Safety (incidence of serious adverse events) [ Time Frame: 1.5 years ]
- Safety (incidence of Grade3-5 Avastin related events) [ Time Frame: 1.5 years ]
- Progression-free survival [ Time Frame: 1.5 years ]
- Duration of survival [ Time Frame: 1.5 years ]
- Safety (incidence of Avastin related adverse of special interest) [ Time Frame: 1.5 years ]
- Type of treatment regimen [ Time Frame: 1.5 years ]
- Reason for treatment discontinuation [ Time Frame: 1.5 years ]
- Difference of patient demographics in this trial and in other studies [ Time Frame: 1.5 years ]
- Treatment compliance [ Time Frame: 1.5 years ]
- Treatment regimen for metastatic colorectal cancer after 1st line treatment with chemotherapy and Avastin [ Time Frame: 1.5 years ]
- Quality of Life questionnaire (EQ-5D 5L) [ Time Frame: 1.5 years ]
- Burden of Illness questionnaire [ Time Frame: 1.5 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Metastatic colorectal cancer with no previous systemic treatment for advanced disease
- Receiving Avastin in combination with a first-line standard of care chemotherapy regimen
- Avastin initiated at the same time as first-line chemotherapy regimen
Exclusion Criteria:
- Investigational, non-standard of care first-line chemotherapy regimen for treatment of metastatic colorectal cancer
- Contraindication to Avastin

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01506167
United Kingdom | |
Bath, United Kingdom, BA1 3NG | |
Berkshire, United Kingdom, SL2 4HL | |
Birmingham, United Kingdom, B15 2TH | |
Birmingham, United Kingdom, B9 5SS | |
Bishop Auckland, United Kingdom, DL14 6AD | |
Blackpool, United Kingdom, FY3 8NR | |
Bradford, United Kingdom, BD9 6RJ | |
Bristol, United Kingdom, BS2 8ED | |
Bury St Edmunds, United Kingdom, IP33 2QZ | |
Canterbury, United Kingdom, CT1 3NG | |
Carlisle, United Kingdom, CA2 7HY | |
Chelsmford, United Kingdom, CM1 7ET | |
Cleveland, United Kingdom, TS19 8PE | |
Cottingham, United Kingdom, HU16 5JQ | |
Darlington, United Kingdom, DL3 6HX | |
Dudley, United Kingdom, DY1 2HQ | |
Durham, United Kingdom, DH15TW | |
Harrogate, United Kingdom, HG2 8AY | |
Harrow, United Kingdom, HA1 3UJ | |
Ipswich, United Kingdom, IP4 5PD | |
Kidderminster, United Kingdom, DY11 6RJ | |
London, United Kingdom, NW3 2QG | |
London, United Kingdom, SE1 9RT | |
London, United Kingdom, SE18 4QH | |
Macclesfield, United Kingdom, SK10 3BL | |
Maidstone, United Kingdom, ME16 9QQ | |
Middlesborough, United Kingdom, TS4 3BW | |
Newcastle upon Tyne, United Kingdom, NE7 7DN | |
North Shields, United Kingdom, NE29 8NH | |
Northwood, United Kingdom, HA6 2RN | |
Nottingham, United Kingdom, NG5 1PB | |
Peterborough, United Kingdom, PE3 9GZ | |
Plymouth, United Kingdom, PL6 8DH | |
Romford, United Kingdom, RM7 0AG | |
Scunthorpe, United Kingdom, DN16 7BH | |
Stafford, United Kingdom, ST16 3SA | |
Sutton, United Kingdom, SM2 5PT | |
Swindon, United Kingdom, SN3 6BB | |
Torquay, United Kingdom, TQ2 7AA | |
Truro, United Kingdom, TR1 3LJ | |
Walsall, United Kingdom, WS2 9PS | |
Winchester, United Kingdom, SO22 5DG | |
Wolverhampton, United Kingdom, WV10 0QP |
Study Director: | Clinical Trials | Hoffmann-La Roche |
Responsible Party: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT01506167 History of Changes |
Other Study ID Numbers: |
ML27971 |
First Posted: | January 9, 2012 Key Record Dates |
Last Update Posted: | June 14, 2017 |
Last Verified: | November 2016 |
Additional relevant MeSH terms:
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases |
Intestinal Diseases Rectal Diseases Bevacizumab Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents |